Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.
Neural circuits of the basal ganglia are critical for motor planning and action selection. Two parallel basal ganglia pathways have been described, and have been proposed to exert opposing influences on motor function. According to this classical model, activation of the 'direct' pathway facilitates movement and activation of the 'indirect' pathway inhibits movement. However, more recent anatomical and functional evidence has called into question the validity of this hypothesis. Because this model has never been empirically tested, the specific function of these circuits in behaving animals remains unknown. Here we report direct activation of basal ganglia circuitry in vivo, using optogenetic control of direct- and indirect-pathway medium spiny projection neurons (MSNs), achieved through Cre-dependent viral expression of channelrhodopsin-2 in the striatum of bacterial artificial chromosome transgenic mice expressing Cre recombinase under control of regulatory elements for the dopamine D1 or D2 receptor. Bilateral excitation of indirect-pathway MSNs elicited a parkinsonian state, distinguished by increased freezing, bradykinesia and decreased locomotor initiations. In contrast, activation of direct-pathway MSNs reduced freezing and increased locomotion. In a mouse model of Parkinson's disease, direct-pathway activation completely rescued deficits in freezing, bradykinesia and locomotor initiation. Taken together, our findings establish a critical role for basal ganglia circuitry in the bidirectional regulation of motor behaviour and indicate that modulation of direct-pathway circuitry may represent an effective therapeutic strategy for ameliorating parkinsonian motor deficits.
Kravitz
Alexxai V
AV
Gladstone Institute of Neurological Disease, 1650 Owens St, San Francisco, California 94158, USA.
Freeze
Benjamin S
BS
Parker
Philip R L
PR
Kay
Kenneth
K
Thwin
Myo T
MT
Deisseroth
Karl
K
Kreitzer
Anatol C
AC
D000818:Animals; D001479:Basal Ganglia / Q000166:cytology* / Q000473:pathology / Q000502:physiology / Q000503:physiopathology*; D000075402:Channelrhodopsins; D022202:Chromosomes, Artificial, Bacterial / Q000235:genetics; D004195:Disease Models, Animal; D005684:Gait; D018476:Hypokinesia / Q000150:complications / Q000235:genetics / Q000503:physiopathology; D019426:Integrases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D008959:Models, Neurological; D009043:Motor Activity / Q000502:physiology; D017072:Neostriatum / Q000166:cytology / Q000473:pathology / Q000502:physiology / Q000503:physiopathology; D009434:Neural Pathways / Q000166:cytology / Q000473:pathology / Q000502:physiology / Q000503:physiopathology*; D009474:Neurons / Q000166:cytology / Q000473:pathology / Q000502:physiology; D016627:Oxidopamine; D010300:Parkinson Disease / Q000150:complications / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology*; D011597:Psychomotor Performance; D011954:Receptors, Dopamine / Q000235:genetics
D000075402:Channelrhodopsins; D011954:Receptors, Dopamine; D016627:Oxidopamine; C045073:Cre recombinase; D019426:Integrases